UT Health San Antonio becomes first civilian center in South Texas to launch FDA-approved radiotherapy treatment for advanced prostate cancer

Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO, Oct. 6, 2023 – The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announces the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer. Approved by the U.S. Food and Drug Administration in March of 2022, Pluvicto […]